Clinical features of 52 neonates with hyperinsulinism.
P de Lonlay-Debeney, F Poggi-Travert, J C Fournet...
https://pubmed.ncbi.nlm.nih.gov/10202168/Actively Recruiting
Led by Cook Children's Health Care System · Updated on 2024-07-16
250
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are studying congenital hyperinsulinism HI and insulinoma, conditions where the pancreas produces too much insulin, causing dangerously low blood sugar levels that can lead to brain damage in newborns and children. This study evaluates whether an investigational drug called Fluorodopa F 18, used with a PET scan combined with CT imaging, can accurately locate areas of the pancreas causing the disease. The goal is to help surgeons remove only the affected part, potentially curing the patient and preventing further brain injury. Participants will receive a dose of Fluorodopa F 18 injected into a vein, followed by PET imaging for up to 70 minutes, alongside a CT scan with contrast to create detailed pancreatic images. These images will be compared to surgical biopsy results to assess accuracy. The study aims to determine the best way to interpret scan results and whether the imaging technique can guide successful surgery for both congenital HI and insulinoma. During the study, researchers will monitor the radioactivity of Fluorodopa F 18 after injection and compare the imaging findings with tissue samples obtained during surgery. The study includes patients who have not responded to medical treatment and are recommended for surgery. The primary outcome is the scans accuracy in locating problematic pancreatic areas. Participants will be observed up to one month after surgery, with safety and imaging effectiveness evaluated throughout the process.
CONDITIONS
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
D
Deborah Rafferty, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cook Children's Health Care System
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PET/CT scan with intravenous 18F-Fluorodopa | Conventional imaging (CT or MRI) for localization |
|---|---|---|
| What it is | A PET/CT imaging procedure where intravenous 18F-Fluorodopa is used to visualize focal pancreatic lesions causing excess insulin production. | Standard imaging approaches such as contrast-enhanced CT or MRI are used to locate focal or diffuse pancreatic lesions before surgery. |
| Role in the study | The investigational method being evaluated for its diagnostic accuracy in distinguishing focal from diffuse disease and localizing lesions before surgery. | Routine clinical imaging tests performed in children being considered for surgical intervention in HI/insulinoma. |
| Primary use | To identify and localize focal lesions of the pancreas that cause hyperinsulinism and guide surgical management. | To assist in anatomical localization of focal or diffuse pancreatic changes prior to potential surgical intervention. |
| How it is performed | Participants receive an intravenous injection of 18F-Fluorodopa, followed by a PET scan lasting up to 70 minutes and an abdominal CT scan with intravenous contrast. | Participants undergo contrast-enhanced abdominal CT and/or MRI scans as per routine clinical practice. |
| Evidence status | Multiple studies in specialized centers report high accuracy for 18F-Fluorodopa PET in detecting and localizing focal pancreatic lesions in congenital hyperinsulinism. | Standard CT/MRI imaging is helpful for detecting gross pancreatic abnormalities but has limited sensitivity for localizing small or subtle focal lesions compared to PET. |
| Important limitations | PET imaging with 18F-Fluorodopa requires access to specialized facilities and radiotracer; there may be limited availability and need for anesthesia in young children. False positives/negatives are possible. | Conventional CT and MRI sometimes fail to detect or localize small focal lesions, which may lead to extensive surgery or missed diagnosis. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 day
Participants receive an injection of Fluorodopa F 18 followed by PET imaging and an abdominal CT scan to produce pancreatic images for diagnostic purposes.
1 imaging visit (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
P de Lonlay-Debeney, F Poggi-Travert, J C Fournet...
https://pubmed.ncbi.nlm.nih.gov/10202168/Timo Otonkoski, Kirsti Näntö-Salonen, Marko Seppänen...
https://pubmed.ncbi.nlm.nih.gov/16380471/Pieter L Jager, Raman Chirakal, Christopher J Marriott...
https://pubmed.ncbi.nlm.nih.gov/18344441/K Mohnike, O Blankenstein, H Minn...
https://pubmed.ncbi.nlm.nih.gov/18547951/Olga T Hardy, Miguel Hernandez-Pampaloni, Janet R Saffer...
https://pubmed.ncbi.nlm.nih.gov/17236890/Mariko Suchi, Paul S Thornton, N Scott Adzick...
https://pubmed.ncbi.nlm.nih.gov/15371948/Olga T Hardy, Miguel Hernandez-Pampaloni, Janet R Saffer...
https://pubmed.ncbi.nlm.nih.gov/17895314/Cook Children's Health Care System
Lead Sponsor